ASH2021注目テーマ「Late-Breaking Abstracts Session #1」

未治療DLBCLにおけるpola-R-CHP療法の
有用性が認められる：POLARIX試験 The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (#LBA-1)

Hervé Tilly（Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, France）